Interleukin-12 (IL-12) is a multifunctional cytokine predominantly produced by activated inflammatory cells. IL-12 plays a pivotal role in orchestrating the immune response of Th1 cells, promoting interferon (IFN-γ) production, and enhancing the activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. Preclinical investigations have highlighted IL-12's ability to stimulate T cells and NK cells within the tumor microenvironment, leading to potent anti-tumor effects, thereby positioning IL-12 as a promising therapeutic target. GemPharmatech developed a novel mouse model expressing human IL-12RB1 and IL-12RB2 (BALB/c-hIL-12RB1/hIL-12RB2), providing a powerful tool to evaluate novel human IL-12 therapeutics.